Background: The relationship between predialysis blood pressure (BP) and hemodialysis (HD) patient outcomes is controversial. We report the evolution of predialysis BP in incident patients treated with the dry weight method and its relationship with patients’ outcomes. Methods: Between January 2000 and 2009, 308 patients started HD treatment. Fluid was progressively removed. The patients were encouraged to accept long-hour dialysis session and to follow a salt-restricted diet. BP and body weight (BW) were recorded and analyzed at start (week 1, W1) and weeks 8, 12, 26 and 52. Results: The predialysis systolic BP decreased from 142.1 at W1 to 130.7 mm Hg at W52. Postdialysis BW decreased from W1 to W8 (–5.0 ± 4.5%). It was correlated with the decrease of the predialysis systolic BP at W26 and W52. Whereas the patient survival was significantly lower in the lower predialysis systolic BP tertile at W1 like in previous reports calling this phenomenon ‘reverse epidemiology’, no relationship between predialysis BP levels and outcomes was found at W12, W26 and W52. The patients in the tertile of the greater predialysis systolic BP decrease at W12 had significantly better survival in the whole group and in hypertensive patients. This relationship remained significant in the Cox proportional-hazards analysis. Conclusions: Hence the dry weight method is efficient in decreasing the predialysis BP in incident HD patients. The initial BW decrease was correlated with BP decrease at W26 and W52. Early correction of BP by fluid removal erases the reverse epidemiology for BP and influences positively the patient survival.

Keywords:
Mortality, Hemodialysis, Incident patients, Dry weight, Blood pressure, Hypertension, Reverse epidemiology
1.
Davenport A, Cox C, Thuraisingham R: Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008;73:759–764.
2.
Goodkin DA, Young EW, Kurokawa K, et al: Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004;44(suppl 2):16–21.
3.
Charra B, Calemard E, Ruffet M, et al: Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286–1291.
4.
Foley RN, Parfrey PS, Harnett JD, et al: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379–1385.
5.
Port FK, Hulbert-Shearon TE, Wolfe RA, et al: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999;33:507–517.
6.
Duranti E, Imperiali P, Sasdelli M: Is hypertension a mortality risk factor in dialysis? Kidney Int Suppl 1996;55:S173–S174.
7.
Kalantar-Zadeh K, Kilpatrick RD, Kopple JD: Reverse epidemiology of blood pressure in dialysis patients. Kidney Int 2005;67:2067–2068.
8.
Salem MM: Treatment of hypertension in the hemodialysis patient: beneficial or not? Curr Hypertens Rep 2000;2:441–444.
9.
Zager PG, Nikolic J, Brown RH, et al: ‘U’ curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998;54:561–569.
10.
Agarwal R: Hypertension and survival in chronic hemodialysis patients – past lessons and future opportunities. Kidney Int 2005;67:1–13.
11.
Agarwal R: Blood pressure and mortality among hemodialysis patients. Hypertension 2010;55:762–768.
12.
Twardowski SJ: Sodium, hypertension, and an explanation of the ‘lag phenomenon’ in hemodialysis patients. Hemodial Int 2008;12:412–425.
13.
Charra B, Laurent G, Chazot C, et al: Clinical assessment of dry weight. Nephrol Dial Transplant 1996;11(suppl 2):16–19.
14.
Scribner BH, Buri R, Caner JE, et al: The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Artif Intern Organs 1960:6:114–122.
15.
Chazot C, Charra B, Vo Van C, Jean G, Vanel T, Calemard E, Terrat JC, Ruffet M, Laurent G: The Janus-faced aspect of ‘dry weight’. Nephrol Dial Transplant 1999;14:121–124.
16.
Charra B, Bergstrom J, Scribner BH: Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998;32:720–724.
17.
Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009;53:500–507.
18.
Töz H, Ozkahya M, Ozerkan F, et al: Improvement in ‘uremic’ cardiomyopathy by persistent ultrafiltration. Hemodial Int 2007;11:46–50.
19.
Wizemann V, Schilling M: Dilemma of assessing volume state – the use and the limitations of a clinical score. Nephrol Dial Transplant 1995;10:2114–2117.
20.
Chan CT, Harvey PJ, Böger R, et al: Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol 2005;25:2685–2686.
21.
Wabel P, Moissl U, Chamney P, et al: Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Nephrol Dial Transplant 2008;23:2965–2971.
22.
Chazot C, Vo-Van C, Zaoui E, et al: Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol Dial Transplant, 2011.
23.
Movilli E, Gaggia P, Zubani R, et al: Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007;22:3547–3552.
24.
Saran R, Bragg-Gresham JL, Levin NW, et al: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222–1228.
25.
Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011;79:250–257.
26.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925–1931.
27.
McIntyre CW: Recurrent circulatory stress: the dark side of dialysis. Semin Dial 2010;23:449–451.
28.
Wizemann V, Wabel P, Chamney P, et al: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009;24:1574–1579.
29.
Ozkahya M, Töz H, Unsal A, et al: Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 1999;34:218–221.
30.
Kayikcioglu M, Tumuklu M, Ozkahya M, et al: The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 2009;24:956–962.
31.
http://www.who.int/dietphysicalactivity/Salt_Report_VC_april07.pdf: Reducing salt intake in populations. Report of a WHO forum and technical meeting. Paris, WHO, 2006.
32.
Canaud B: Residual renal function: the delicate balance between benefits and risks. Nephrol Dial Transplant 2008;23:1801–1805.
33.
Inrig JK, Patel UD, Toto RD, Szczech LA: Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009; 54:881–890.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.